Biotech Kate Sheridan STAT Plus: The field is exploding, but microbiome therapeutics still face a wave of challenges
First Opinion Andrew Thomson, Brian Carpenter and Robert Broadnax STAT Plus: Developers of microbiome-based drugs face challenges. There are ways to overcome them
In the Lab Kate Sheridan STAT Plus: New research underscores the link between multiple sclerosis and the gut microbiome
Health Kate Sheridan STAT Plus: One dead, four hospitalized after receiving OpenBiome stool transplants
Health Kate Sheridan Massachusetts General Hospital oversaw trial that led to the first death from a fecal transplant, a new paper shows
Biotech Megan Thielking STAT Plus: Biotech, but make it beauty: Startups look to viruses and bacteria for the next generation of skin care
Biotech Kate Sheridan STAT Plus: New research exploring centenarians’ gut microbiomes reveals a potential clue to their longevity
Biotech Kate Sheridan STAT Plus: Seres Therapeutics’ microbiome therapy for ulcerative colitis falls short in Phase 2 trial
Biotech Kate Sheridan STAT Plus: Nestlé Health Science will split profits from Seres microbiome drug, if it’s approved
Biotech Kate Sheridan STAT Plus: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives
Biotech Erin Brodwin STAT Plus: SEC charges co-founders of shuttered microbiome startup uBiome with $60 million fraud
Biotech Kate Sheridan STAT Plus: Fecal matter transplants could help certain cancer drugs work in more people, study shows
Biotech Kate Sheridan STAT Plus: Months of limbo at OpenBiome put fecal matter transplants on hold across the country
Biotech Kate Sheridan STAT Plus: Seres announces positive late-stage results for its microbe-based drug
Biotech Kate Sheridan STAT Plus: Finch touts positive results for its microbiome pill for C. diff infections
Health Natalya Ortolano STAT Plus: A patient’s microbiome could have a major impact on how drugs affect them, new research confirms
In the Lab Elizabeth Cooney STAT Plus: Bacteria are widespread in tumors, forming distinct populations depending on the cancer type
Biotech Kate Sheridan STAT Plus: ‘Good’ bacteria could help fight a common vaginal infection, new data show
Biotech Kate Sheridan STAT Plus: Rebiotix unveils positive — but preliminary — data on its microbiome drug for C. diff infections
Health Kate Sheridan STAT Plus: Within months of birth, some pathogens are detectable in infants’ guts, new research shows
Health Kate Sheridan STAT Plus: CDC credits a sharp decline in C. diff infections to checklists and better antibiotic stewardship
Biotech Kate Sheridan STAT Plus: Despite coronavirus disruption, major microbiome companies are cautiously optimistic about upcoming data
Biotech Rebecca Robbins STAT Plus: Microbial signatures in the blood could offer new avenue for liquid biopsies to detect cancer
Biotech Kate Sheridan STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
Biotech Erin Brodwin STAT Plus: Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation
Biotech Kate Sheridan STAT Plus: After an unprecedented death, FDA is offered divergent forecasts on future of fecal transplants
Biotech Kate Sheridan STAT Plus: FDA to consider new evidence, risks behind fecal matter transplants for C. diff treatment
Biotech Kate Sheridan STAT Plus: The next frontier for the microbiome: vaginal fluid transplants that take aim at a common condition
Pharmalot Elizabeth Cooney STAT Plus: Pharmalittle: Medicare will cover CAR-T; Trump health care overhaul in the wings